Medical Device

More Patients in Canada Are Now Candidates for a Leadless Pacing Option

Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) announced today that it has received a Health Canada licence for Micra™ AV, the world's smallest pacemaker with atrioventricular (AV) synchrony. Micra AV is indicated for the treatment of patients with AV block, a condition in which the electrical connection between the chambers of the heart (the atria and the ventricle) is impaired. Medtronic's groundbreaking technology is the first and currently the only Health Canada-licensed leadless pacemaker portfolio, now expanding the range of eligible Canadian patients that can be implanted.

Micra AV in hand (CNW Group/Medtronic Canada ULC)

Historically, patients with AV block had traditional dual-chamber pacemakers implanted in the upper chest, below the collar bone, and connected to the heart using thin wires called "leads." Identical in size and shape to the original leadless Micra Transcatheter Pacing System (TPS), Micra AV has several additional features, including internal atrial sensing algorithms which detect cardiac movement, allowing the device to adjust pacing in the ventricle to coordinate with the atrium, providing "AV synchronous" pacing therapy to patients with AV block.

"With the licensing of Micra AV, more patients will benefit from a new way to implant pacemakers," say Dr. Blandine Mondésert, cardiac electrophysiologist at the Montreal Heart Institute, and associate professor at Université de Montréal. "The advantages of leadless pacing include a better quality of pacing, fewer complications related to the leads and pacemaker pocket, cosmetic implantation, and atrioventricular synchronization in patients in sinus rhythm. Real-world use of Micra has shown a 63% reduction in major complications compared to traditional transvenous pacemakers i . Especially in older patients, but also in younger ones, it is a game-changer."

The MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study, published in JACC: Clinical Electrophysiology ,  evaluated the safety and effectiveness of accelerometer-based atrial sensing algorithms. The study assessed the ability of the Micra's internal sensor to monitor and detect atrial contractions and enable coordinated pacing between the atrium and ventricle, thereby providing AV synchrony. Results from the study, presented at the American Heart Association 2019 Scientific Sessions, showed the primary efficacy objective was met, with a significantly greater percentage of complete heart block patients with normal sinus rhythm having > 70% AV synchrony during algorithm-mediated AV synchronous pacing (38 of 40 patients, 95%) than VVI pacing (0 patients, P > 70% synchrony). The study's primary safety objective was also met, with no pauses or episodes of pacing-induced tachycardia reported during algorithm mediated AV synchronous pacing.

"Medtronic remarkably changed healthcare 63 years ago with the first battery powered pacemakers, and we are proud to continue pioneering in the field of pacing by offering the first miniaturized, leadless pacing portfolio," said Mitch Leschuk , senior director of the Cardiovascular portfolio at Medtronic Canada. "Micra AV reinvents our own innovation, expanding the benefits of leadless pacemakers to more patients."

About the Micra Transcatheter Pacing System (TPS)
Licensed by Health Canada in 2016, the Micra TPS is a leadless pacemaker option for patients who only require pacing in the right ventricle. Comparable in size to a large vitamin capsule, Micra is less than one-tenth the size of traditional pacemakers yet delivers advanced pacing technology to patients via a minimally invasive approach. During the implant procedure, the device is attached to the heart with small tines and delivers electrical impulses that pace the heart through an electrode at the end of the device.

Unlike traditional pacemakers, Micra does not require leads or a surgical "pocket" under the skin, so potential sources of complications related to leads and pockets are eliminated - as are any visible signs of the device.

About Medtronic Canada ULC
Proudly serving Canadian healthcare for over 50 years, Medtronic Canada ULC ( www.medtronic.ca ), is a subsidiary of Medtronic plc, the world's largest medical technology, services, and solutions companies — alleviating pain, restoring health, and extending life for millions of people around the world. Serving physicians, hospitals, and patients across the country, Medtronic Canada ULC is headquartered in Brampton, Ontario , with regional offices in Montreal and Vancouver , and a Medtronic Resource Centre in Surrey, BC . The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

_________________________

i El-Chami et al Micra Updated Real-World Performance DOI: https://doi.org/10.1016/j.hrthm.2018.08.005

Medtronic Canada ULC Logo (CNW Group/Medtronic Canada ULC)

SOURCE Medtronic Canada ULC

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2020/21/c5414.html

News Provided by Canada Newswire via QuoteMedia

8 Surgical Robotics Stocks

8 Surgical Robotics Stocks

Robotics technology is quickly disrupting a variety of sectors, including the medical space, and surgical robot applications are a major component of the overall medical robots market.

In fact, a Strategic Market Research report projects that this industry will reach a value of US$20.98 billion by 2030, up from an estimated US$4.42 billion in 2020. According to the firm, the increased need for procedure-specific surgical robots and advancements in medical robot technology are seen as the main drivers of this sector.

Surgical robotics companies are developing products for a variety of surgery types, including cardiac, spinal and endoluminal. The tools these firms provide can increase surgeons’ performance ability and can lessen scarring, incisions, blood loss and more. They can also make surgeries safer and lead to a more comfortable recovery.

Keep reading...Show less
Applied UV

Applied UV Files Trademark Infringement Lawsuit Against Aeroclean Technologies

Applied UV, Inc. (NasdaqCM: AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced that its wholly-owned subsidiary, Sterilumen, Inc., has filed a lawsuit in the amount of $20 million against Aeroclean Technologies, Inc. (NASDAQ: AERC) and its predecessor, Aeroclean Technologies, LLC, for trademark infringement, unfair competition and damaging Sterilumen.

John F. Andrews, Applied UV's CEO and Director, stated, "Protecting our brand, Airoclean(TM), and trademarked products and technologies is crucial, and we will vigorously defend against infringements. Sterilumen is the owner of 29 issued patents and 18 pending patent applications and five 'AIRO' trademarks, including Airoclean(TM), in 19 countries, all of which are for use in connection with our air purification products. Significant resources have been invested to develop the products, and we currently possess a number of issued patents and pending patent applications with respect to both the AIRO products and the related technologies. Our brand is under attack by a new market entrant, Aeroclean, that improperly adopted and began to use a mark in connection with its own air purification products that we believe infringes on our trademark rights, creates confusion for buyers and violates fair competition practices."

Keep reading...Show less

Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has assumed full commercial activities and is re-launching Exelon ® (rivastigmine) in Brazil following successful transfer of the marketing authorization.

On May 26, 2021, Knight completed the acquisition of the exclusive rights to manufacture, market and sell Exelon ® in Canada and Latin America as well as the exclusive license to use the intellectual property and the Exelon trademark, from Novartis within those territories.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Johnson & Johnson Ends Global Sales of Cancer-Causing Baby Powder Amid Increased Scrutiny from Consumer Litigation, Science

Courts continue to scrutinize J&J's controversial bankruptcy ploy to avoid liability

Legal experts say the decision by Johnson & Johnson (NYSE: JNJ) to halt future sales and distribution of talc-based products worldwide, including its iconic Johnson's Baby Powder, points to mounting pressure on the company to resolve tens of thousands of legal claims brought by ovarian cancer and mesothelioma victims.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Medical Device Stocks: 5 Biggest Companies in 2022

Medical Device Stocks: 5 Biggest Companies in 2022

The top medical device companies are a vital component of the overarching life science industry, as well as a major force in treating many diseases and conditions.

The global medical device market was valued at US$434.2 billion in 2021, and is expected to grow at a compound annual growth rate of 6.3 percent to reach US$625.3 billion in 2027.

Growth in the global medical device industry is tied to the rapid rise of an aging population, increased infectious and chronic diseases, as well as technological advancements in both the field of life science and in emerging technologies such as 3D printing, robotics and the internet of things.

Keep reading...Show less

New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions

  • The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
  • Researchers used Abbott's i-STAT™ TBI Plasma test – the only FDA-cleared rapid test on a portable analyzer for concussion – and Abbott's core laboratory ARCHITECT instrument to measure two biomarkers in blood plasma associated with brain injury

A new study published in The Lancet Neurology demonstrates the ability of two blood-based biomarkers to predict how someone will recover from traumatic brain injury (TBI). Testing for these two biomarkers in the immediate aftermath of an injury can help health care providers determine the best way to treat and care for patients.

This research shows that when a clinician conducts a blood test for these brain proteins soon after a possible injury, they quickly get a more accurate picture of how severe the injury is, the expected course of recovery and the longer-term implications of the TBI. The markers were measured using Abbott's i-STAT™ TBI Plasma test , as well as on the company's ARCHITECT core laboratory instrument using research prototype assays, both of which helped predict recovery.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×